PPParaskevi-Maria Psefteli

Paraskevi-Maria Psefteli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paraskevi-Maria Psefteli has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Giovanni Enrico Mann

    King's British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, Faculty of Life Sciences & Medicine, King's College London, 150 Stamford Street, London, SE1 9NH, UK

    3 shared publications
  • Paul D. Taylor

    Department of Women and Children’s Health, School of Life Course and Population Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK

    3 shared publications
  • Sarah J. Chapple

    King's British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences, Faculty of Life Sciences & Medicine, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom

    3 shared publications
  • Alokya Balagamage

    2 shared publications
  • Jessica Morris

    2 shared publications
  • Elisabeth Ehler

    Randall Center for Cell and Molecular Biophysics and School of Cardiovascular Medicine and Sciences, King's College London, United Kingdom

    1 shared publication

Latest Publications

  • At the heart of the matter: Nrf2 modulates offspring cardiovascular phenotype following obese/GDM pregnancy

    by Paraskevi-Maria Psefteli, Jessica K. Morris, Paul D. Taylor, Elisabeth Ehler, Luigi Gnudi, Giovanni E. Mann, Sarah J. Chapple

  • Effect of sulforaphane, an activator of the Nrf2 antioxidant defence pathway, on maternal adiposity in a model of diet-induced insulin resistant pregnancy

    by Alokya Balagamage, Paraskevi-Maria Psefteli, Jessica Morris, Paul Taylor, Giovanni Mann, Sarah Chapple

    The incidence of maternal obese and/or gestational diabetic (GDM) pregnancy are increasing globally, with ~10-20% of mothers classified as obese and/or GDM within the U.K. Both obese and GDM pregnancy are associated with increased risk of cardiometabolic disease, with mothers and their children at greater risk of developing later-life Type 2 diabetes, obesity and/or cardiovascular disease. Higher adiposity in pregnancy leads to increased inflammation, which may be countered by antioxidant defence genes regulated by the transcription factor Nrf2. Dietary activators of Nrf2 such as sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables such as broccoli, may therefore be used as anti-obesogenic cardiovascular protectants. In this study we examined the effect of SFN on maternal adiposity. C57BL/6 WT and Nrf2 deficient dams were fed a highly palatable obesogenic diet 6 weeks prior to pregnancy, then received with vehicle (corn oil) or SFN throughout pregnancy and the postpartum period. Inguinal and parametrial fat pads were weighed at termination, tissued fixed with 5µm sections stained with H&E to measure adipocyte area. SFN treatment reduced maternal inguinal and to a lesser extent parametrial adipose depots in WT dams. Nrf2 deficient dams treated with SFN showed no change in adipose fat pad mass. Preliminary data showed parametrial adipocyte area was reduced by SFN treatment in WT not Nrf2 deficient dams, however Nrf2 deficiency by itself resulted in a reduced adipocyte size. In summary, SFN has anti-adipogenic properties and appears to mediate its effects through Nrf2, however Nrf2 deficiency by itself alters adipose morphology.

  • Nrf2 activator Sulforaphane attenuates maternal adiposity and hepatic steatosis

    by Paraskevi-Maria Psefteli, Alokya Balagamage, Jessica Morris, Paul Taylor, Giovanni Mann, Sarah Chapple

    Intro/Aims: Maternal obesity is a major risk factor for the development of first onset of diabetes in pregnancy, also known as gestational diabetes mellitus (GDM). Recent studies also indicate that non-alcoholic fatty liver disease (NAFLD) is an independent predictor of GDM. Sulforaphane (SFN) is a well-known dietary activator of the redox-sensitive transcription factor Nrf2, with reported anti-adipogenic and NAFLD ameliorating effects in non-pregnant obese rodent models. In this study we sought to determine whether sulforaphane could exert metabolic protection in GDM murine dams. Methods: Wildtype (WT) and Nrf2 deficient C57BL/6 dams were fed a highly palatable obesogenic diet 6 weeks prior to pregnancy, then received either vehicle (corn oil) or SFN throughout pregnancy and the postpartum period. Bodyweight was measured throughout the developmental period, with visceral and subcutaneous adiposity (parametrial and inguinal fat pads, respectively measured relative to bodyweight and tibia length) determined upon post-partum termination. H&E staining of liver tissue was used to quantify maternal steatosis. Results: SFN significantly reduced postnatal weight retention, with a reduction in subcutaneous inguinal adipose tissue depots noted in WT not Nrf2 deficient dams. Preliminary results also indicate that hepatic lipid deposition quantified as % lipid area and mean lipid area were also attenuated by SFN intervention in WT not Nrf2 deficient dams. Conclusion: SFN exerts maternal metabolic protection against obesogenic dietary feeding, reducing subcutaneous adipose deposition as well as liver lipid accumulation. Protection is ameliorated in Nrf2 deficient dams suggesting that SFNs protective effects are mediated via Nrf2 activation.